Suppr超能文献

使用 Lucira™ Check It COVID-19 检测试剂盒快速检测 SARS-CoV-2。

Rapid SARS-CoV-2 Detection Using the Lucira™ Check It COVID-19 Test Kit.

作者信息

Zahavi Maya, Rohana Hanan, Azrad Maya, Shinberg Bracha, Peretz Avi

机构信息

The Clinical Microbiology Laboratory, Baruch Padeh Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Poriya, Tiberias 1528001, Israel.

Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.

出版信息

Diagnostics (Basel). 2022 Aug 3;12(8):1877. doi: 10.3390/diagnostics12081877.

Abstract

The need for the early identification of SARS-CoV-2 has let to a quest for reliable tests that meet the standards of polymerase chain reaction (PCR) tests, on the one hand, and are low-cost, easy-to-use, and fast, on the other hand. One such test is the Lucira™ Check It COVID-19 Test kit (“Lucira”) (Lucira Health, Inc., Emeryville, CA, USA), which utilizes real-time loop-mediated isothermal amplification technology, developed for at-home use. This study evaluated the clinical sensitivity and specificity of Lucira in identifying the virus in 190 nasopharyngeal samples collected between January and October 2021. Each sample was also subjected to RT-PCR. All negative RT-PCR results were paralleled by a negative Lucira result. Out of 90 participants who had a positive RT-PCR result, 82 (91.1%) tested positive by Lucira. Among the 72 symptomatic participants, 67 (93%) tested positive by Lucira. All samples with a positive RT-PCR result with a threshold cycle (Ct) > 36, yielded a negative Lucira result. In addition, a significant positive correlation was found between Ct and time-to-positivity with Lucira (R = 0.8612, p < 0.0001). The implementation of such a portable and affordable assay may aid in breaking the COVID-19 transmission chain.

摘要

对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进行早期识别的需求,一方面促使人们寻求符合聚合酶链反应(PCR)检测标准的可靠检测方法,另一方面要求检测方法低成本、易于使用且快速。其中一种检测方法是Lucira™ Check It COVID-19检测试剂盒(“Lucira”)(美国加利福尼亚州埃默里维尔市的Lucira Health公司),该试剂盒采用实时环介导等温扩增技术,专为家庭使用而开发。本研究评估了Lucira在识别2021年1月至10月期间采集的190份鼻咽样本中的病毒时的临床敏感性和特异性。每个样本也进行了逆转录聚合酶链反应(RT-PCR)检测。所有RT-PCR检测结果为阴性的样本,Lucira检测结果也为阴性。在90名RT-PCR检测结果为阳性的参与者中,82人(91.1%)通过Lucira检测呈阳性。在72名有症状的参与者中,67人(93%)通过Lucira检测呈阳性。所有RT-PCR检测结果为阳性且阈值循环数(Ct)>36的样本,Lucira检测结果均为阴性。此外,还发现Ct与Lucira检测呈阳性的时间之间存在显著正相关(R = 0.8612,p < 0.0001)。实施这样一种便携式且价格实惠的检测方法可能有助于打破新冠病毒的传播链。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/9406928/4a31115e1e5b/diagnostics-12-01877-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验